BE1031639B1 - Pharmaceutical composition for the treatment of porcine reproductive and respiratory syndrome virus - Google Patents

Abstract

The present invention provides a pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus and an application thereof, which comprises calycosin and pinoresinol diglucoside as active ingredients. The pharmaceutical composition is environmentally friendly, does not contain antibiotics, is healthy and has no drug resistance, so that it can be well used for treating pigs infected with porcine reproductive and respiratory syndrome virus; and the pharmaceutically active ingredients in the present pharmaceutical composition are defined, which helps to reduce the damaging effect of other ingredients in the traditional Chinese medicine preparation on the liver, heart, spleen, lungs and kidneys of pigs.

Description

1 BE2024/5327

Pharmaceutical composition for the treatment of porcine reproductive and respiratory syndrome virus

Technical field

The present invention relates to the veterinary field, more particularly, it relates to a pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus and its use.

Prior art

Porcine reproductive and respiratory syndrome, abbreviated PRRS, is a contact infectious disease characterized by reproductive disorders in sows and respiratory diseases in piglets of all ages, caused by porcine reproductive and respiratory syndrome virus. This disease is rapidly spreading and is an acute disease with a high mortality rate caused by a highly pathogenic mutant strain of porcine reproductive and respiratory syndrome virus.

Clinically, many pregnant sows abort en masse, give birth to dead fetuses, deliver prematurely, or give birth to weak piglets, with an abortion rate in pregnant sows reaching 30%, sometimes as high as 70% or even 80%; lactating sows suffer from severe milk deficiency or even no milk; piglet mortality varies with age, reaching 80% to 100% before 10 days of age, usually between 20% and 80% after 10 days; growing and finishing pigs show symptoms of respiratory infections, with a high incidence rate of PRRS in finishing pigs reaching 50% to 80%, sometimes more than 80%. PRRS is one of the most serious diseases currently affecting the global swine industry, spreading rapidly since its discovery, and to date only a few countries have not been affected by this disease.

Currently, the common method of preventing and treating PRRS in pigs is to vaccinate pigs against PRRS virus and use antibiotics for treatment, but the results are not satisfactory. During the seasons and in the regions where PRRS is prevalent, most pig farmers suffer heavy losses with a high mortality rate exceeding 50%, causing

2 BE2024/5327 thus great losses. Currently, the use of traditional Chinese medicine to prevent and treat PRRS has become a new field of research.

For example, Chinese patent CN103054999B discloses a Chinese herbal preparation and its preparation method for the prevention and treatment of

Highly pathogenic PRRS, comprising the following raw materials by weight: 35 to 65 parts of Radix Bupleuri, 15 to 25 parts of Rhizoma Coptidis, 20 to 40 parts of Cortex Phellodendri, 22 to 58 parts of Radix Scutellariae, 5 to 15 parts of Caulis

Aristolochiae, 5 to 15 parts of Herba Schizonepetae, 15 to 25 parts of Radix — Saposhnikoviae, 45 to 75 parts of Radix Isatidis, 22 to 58 parts of Herba Ephedrae, 35 to 65 parts of Radix Astragali, 30 to 50 parts of Flos Lonicerae, 30 to 40 parts of

Fructus Forsythiae, 20 to 40 parts of Herba Andrographitis, 30 to 50 parts of Folium

Mori. This invention has good effects for the prevention and treatment of

Highly pathogenic PRRS.

For example, Chinese patent CN102078419B discloses a medicine for treating PRRS in pigs, mainly composed of the following raw materials by weight, uniformly crushed and mixed: 9 to 11 parts of Folium

Pinus, 1.5 to 2.5 parts of Pericarpium Citri Reticulatae, 0.8 to 1.2 parts of Radix

Ginseng, 0.8 to 1.2 parts Radix Scutellariae, 0.8 to 1.2 parts Cortex

Phellodendri, 1.5-2.5 parts of Fructus Gardeniae, 1.5-2.5 parts of Radix Isatidis, 0.2-0.4 parts of Radix Glycyrrhizae, 1.5-2.5 parts of Flos Lonicerae, 1.5-2.5 parts of Herba Artemisiae Scopariae, 3.5-4.5 parts of Radix Astragali, 1.5-2.5 parts of Rhizoma Dioscoreae, 0.8-1.2 parts of Flos Chrysanthemi, 1.5-2.5 parts of Radix Typhonii, 0.8-1.2 parts of Radix Astragali Polysaccharides, with better preventive action for pigs not infected with PRRS and good therapeutic effect for pigs with moderate symptoms of PRRS, as well as obvious action of preventing and treating influenza porcine, porcine streptococcal disease and porcine erysipelas.

Although traditional Chinese medicine has made certain progress in the prevention and treatment of PRRS, existing herbal formulations have many defects such as the complexity of composition and the difficulty in controlling product quality, which affects their effective application in the

3 BE2024/5327 prevention and treatment of PRRS. The present invention, by extracting effective components from traditional Chinese medicine, transforms them into a pharmaceutical composition, thereby achieving satisfactory results in the treatment of PRRS in pigs.

Disclosure of the invention

The present invention relates to a pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus. To achieve the objective of the present invention, the following technical solutions are envisaged:

On the one hand, the present invention relates to a pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus, said composition containing the active components rutin and rutoside.

In a preferred embodiment of the present invention, the weight ratio of rutin and rutoside is 1-2:1-2; preferably 1:1.8-2.2; particularly preferable 1:2. By adopting this preferred weight ratio, it contributes to improving the efficacy of the pharmaceutical composition in the treatment of porcine reproductive and respiratory syndrome virus.

In a preferred embodiment of the present invention, the pharmaceutical composition may or may not contain other active components.

In a preferred embodiment of the present invention, the pharmaceutical composition also comprises pharmaceutically acceptable excipients.

In a preferred embodiment of the present invention, the pharmaceutically acceptable excipients comprise solubilizing agents, said agents including but not limited to Tween 20, Tween 80, etc.

4 BE2024/5327

In a preferred embodiment of the present invention, the pharmaceutical composition is a liquid preparation for oral administration.

On the other hand, the present invention relates to the above-mentioned application of the pharmaceutical composition in the prevention and treatment of viruses.

In a preferred embodiment of the present invention, the virus refers to porcine reproductive and respiratory syndrome virus.

The advantages of the present invention over the prior art are as follows: (1) Environmentally friendly, antibiotic-free, healthy, no resistance, can be well used to treat pigs infected with PRRS. (2) The active components of the drug are clear, which helps to reduce the …— damage caused to organs such as liver, heart, spleen, lungs and kidneys of pigs by other components of herbal preparations.

Brief description of the drawings

Figure 1: Photo of fattened pigs with PRRS.

Figure 2: Mental status of the negative control group before the experiment (left) and the group treated with drug 1 (right), both groups of pigs show mental depression, propensity to rest and drowsiness.

Figure 3: Mental status of negative control group (left) and drug 1-treated group (right) after 7 days of experiment, improvement of mental status of drug 1-treated group; most pigs in negative control group tend to rest and be sleepy.

Figure 4: Mental status of drug 1-treated group (left) and drug 2-treated group (right) after 11 days of experiment, good mental status of drug 2-treated group; most pigs in drug 1-treated group tend to rest and be sleepy.

Detailed description of the embodiments

The present invention is described in detail through the following embodiment examples.

Embodiment 1: Preparation of pharmaceutical composition 5 Medicine 1: Dissolve 1 g of rutin, 2 g of rutoside and 2 g of Tween 80 in 500 ml of saline solution to form medicine 1.

Drug 2: Dissolve 1 g rutin, 1.5 g rutoside, and 2 g Tween 80 in 500 mL saline to form Drug 2.

Drug 3: Dissolve 1.5 g rutin, 2 g rutoside, and 2 g Tween 80 in 500 ml saline to form Drug 3.

Control Drug 1: Dissolve 3 g of rutin and 2 g of Tween 80 in 500 ml of saline to form Control Drug 1.

Control Drug 2: Dissolve 3 g of rutoside in 500 ml of saline solution to form Control Drug 2.

Method 2: Evaluation of the clinical effect of drugs on the treatment of PRRS in pigs 1.1 Experimental animals 360 growing pigs, 106 days old, weighing an average of 40 kg, divided into 6 groups of 60 pigs each. 1.2 Experimental location

Livestock farm in Shandong Province, Taian. 2. Methods 2.1 Identification of PRRS outbreak focus before the experiment.

Diagnosis of clinical symptoms:

The main symptoms in growing pigs include pale skin, abdominal breathing, weight loss, diarrhea, ear color change, etc. (as shown in Figure 1).

6 BE2024/5327

Serological diagnosis of PRRS: Serum samples were taken from each group of growing pigs, PRRS antigen positivity rate was 82.2%.

Diagnosis of PRRS by oral fluid sampling: Positivity rate at

PRRS of 83.3%. 2.2 Experimental method

Three treatment groups and two positive control groups receive oral treatment in drinking water for 11 days, at a dose of 2 kg/ton of water, once daily. The negative control group is raised normally without treatment. Samples are taken before the experiment and on the 11th day of the experiment.

Pre-experiment tests: Serological tests + oral fluid tests (to identify the PRRS outbreak focus), Post-experiment tests: Oral fluid tests.

Serological test method: Collection of 4 to 5 ml of anterior venous blood from each pig, centrifugation of the serum obtained, labeling and sending for analysis.

Oral fluid test method: Tie a 1-meter rope to the door of the pig pen, let it stand for 30 minutes, remove and place in a resealable bag, mix with an appropriate amount of saline, transfer to a centrifuge tube, mark and send for analysis. 3. Experiment results 3.1 Mental state

Daily observation of the mental state of the two groups of pigs, photography and recording, the results are shown in Figures 2 to 4. 3.2 Mortality rate and detection of PRRS virus

Recording the number of growing pigs that died on the 11th day of the experiment, sampling and detection of PRRS virus before the experiment and on the 11th day of the experiment, the results of the experiment are shown in Table 1 below.

7 BE2024/5327

Table 1: Mortality rate during the experiment and comparison results of oral fluid for PRRS before and after the experiment

Group Number Positivity rate of the Number of | Mortality oo

Group of 80.0% 0.0% 0.0% este

Group of 83.3% 3.3% 1 1.7% essen

Group of 85.0% 5.0% 0.0% crumbs

Group 81.7% 13.3% 3 5.0% emee DO IE LE

Group 83.3% 16.7% 4 6.7% emee PO

Group 86.7% 28.3% 7 11.7%

EE ee LOTS

The above experiment results show that using the drug of the present invention can effectively reduce the PRRS positivity rate and the mortality rate, especially the proportion shown in embodiment 1 can more effectively reduce the PRRS positivity rate.

Preferred embodiments of the present invention have been described above, but are not intended to limit the invention. Those skilled in the art may make improvements and modifications to the examples described herein without departing from the scope and spirit of the invention as disclosed.

Claims (10)

8 BE2024/5327 Claims 1. A pharmaceutical composition for the treatment of porcine blue ear disease virus, said composition comprising the active ingredients rutin and pine resin glucoside. 2. The pharmaceutical composition according to claim 1, wherein the weight ratio of rutin and pine resin glucoside is 1-2:1-2. 3. The pharmaceutical composition according to claim 1, wherein the weight ratio of rutin and pine resin glucoside is 1:1.8-2.2. 4. The pharmaceutical composition according to claim 1, wherein the weight ratio of rutin and pine resin glucoside is 1:2. 5. The pharmaceutical composition according to any one of claims 1 to 4, said composition comprising or not other active ingredients. 6. The pharmaceutical composition according to any one of claims 1 to 4, said composition also comprising pharmaceutically acceptable excipients. 7. The pharmaceutical composition according to claim 6, wherein the pharmaceutically acceptable excipients comprise solvents. 8. The pharmaceutical composition according to any one of claims 1 to 4, said composition being a liquid preparation for oral administration. 9. The use of the pharmaceutical composition according to any one of claims 1 to 8 in the preparation of medicaments for the prevention and treatment of viruses. 10. The use according to claim 9, wherein the virus refers to porcine blue ear disease virus.